Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,099 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma.
Gauvreau GM, Hohlfeld JM, FitzGerald JM, Boulet LP, Cockcroft DW, Davis BE, Korn S, Kornmann O, Leigh R, Mayers I, Watz H, Grant SS, Jain M, Cabanski M, Pertel PE, Jones I, Lecot JR, Cao H, O'Byrne PM. Gauvreau GM, et al. Among authors: jones i. Eur Respir J. 2023 Mar 9;61(3):2201193. doi: 10.1183/13993003.01193-2022. Print 2023 Mar. Eur Respir J. 2023. PMID: 36822634 Free PMC article. Clinical Trial.
Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study.
Watz H, Hohlfeld JM, Singh D, Beier J, Diamant Z, Liu J, Hua S, Abd-Elaziz K, Pinot P, Jones I, Tillmann HC. Watz H, et al. Among authors: jones i. Respir Res. 2020 Apr 15;21(1):87. doi: 10.1186/s12931-020-01349-5. Respir Res. 2020. PMID: 32295593 Free PMC article. Clinical Trial.
Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial.
Rowe SM, Jones I, Dransfield MT, Haque N, Gleason S, Hayes KA, Kulmatycki K, Yates DP, Danahay H, Gosling M, Rowlands DJ, Grant SS. Rowe SM, et al. Among authors: jones i. Int J Chron Obstruct Pulmon Dis. 2020 Oct 5;15:2399-2409. doi: 10.2147/COPD.S257474. eCollection 2020. Int J Chron Obstruct Pulmon Dis. 2020. PMID: 33116455 Free PMC article. Clinical Trial.
Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial.
Singh D, Wild JM, Saralaya D, Lawson R, Marshall H, Goldin J, Brown MS, Kostikas K, Belmore K, Fogel R, Patalano F, Drollmann A, Machineni S, Jones I, Yates D, Tillmann HC. Singh D, et al. Among authors: jones i. Respir Res. 2022 Feb 10;23(1):26. doi: 10.1186/s12931-022-01949-3. Respir Res. 2022. PMID: 35144620 Free PMC article. Clinical Trial.
Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251).
Kazani S, Rowlands DJ, Bottoli I, Milojevic J, Alcantara J, Jones I, Kulmatycki K, Machineni S, Mostovy L, Nicholls I, Nick JA, Rowe SM, Simmonds NJ, Vegesna R, Verheijen J, Danahay H, Gosling M, Ayalavajjala PS, Salman M, Strieter R. Kazani S, et al. Among authors: jones i. J Cyst Fibros. 2021 Mar;20(2):250-256. doi: 10.1016/j.jcf.2020.11.002. Epub 2020 Dec 6. J Cyst Fibros. 2021. PMID: 33293212 Free PMC article.
Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers.
Sangana R, Xu Y, Shah B, Tian X, Zack J, Shakeri-Nejad K, Kalluri S, Jones I, Ligueros-Saylan M, Taylor AF, Jain DK, Scosyrev E, Uddin A, Laurent N, Paganoni P. Sangana R, et al. Among authors: jones i. Clin Pharmacol Drug Dev. 2024 Feb 22. doi: 10.1002/cpdd.1373. Online ahead of print. Clin Pharmacol Drug Dev. 2024. PMID: 38389387
2,099 results